Bausch Health Companies (TSE:BHC) Upgraded to “Hold” at Jefferies Financial Group

Bausch Health Companies (TSE:BHC) was upgraded by equities researchers at Jefferies Financial Group to a “hold” rating in a report released on Wednesday,Zacks.com reports.

Bausch Health Companies Trading Up 0.9%

TSE:BHC opened at C$6.44 on Wednesday. The company has a debt-to-equity ratio of -1,009.96, a quick ratio of 0.58 and a current ratio of 1.32. Bausch Health Companies has a one year low of C$6.10 and a one year high of C$11.97. The business’s 50-day simple moving average is C$7.07 and its 200 day simple moving average is C$7.71. The stock has a market cap of C$2.41 billion, a price-to-earnings ratio of -1.99, a price-to-earnings-growth ratio of 0.21 and a beta of 0.97.

Bausch Health Companies (TSE:BHC) last issued its quarterly earnings data on Wednesday, April 29th. The company reported C$1.08 earnings per share for the quarter. Bausch Health Companies had a positive return on equity of 120.43% and a negative net margin of 13.54%.The firm had revenue of C$3.51 billion during the quarter. As a group, sell-side analysts predict that Bausch Health Companies will post 5.5472637 earnings per share for the current fiscal year.

About Bausch Health Companies

Bausch Health Companies Inc (NYSE:BHC)(TSX:BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neuroscience, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors.